Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

ABOUT NUCALA

Interleukin 5 (IL-5) is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils

Target IL-5 in severe asthma with NUCALA

Video player requires JavaScript enabled. You can download this video here: https://gskvideo.edgesuite.net/GSKSource/nucala/1000805R0-nucala-moa.mp4

The mechanism of action of mepolizumab in asthma has not been definitely established.
This video illustrates the mechanism of action (MOA) for NUCALA.

The mechanism of action of mepolizumab in asthma has not been definitely established.
This video illustrates the mechanism of action (MOA) for NUCALA.

NUCALA precisely targets IL-5, providing rapid reduction in blood eosinophil levels without complete depletion1,2

  1. *Data based on mepolizumab 75 mg IV (n=10) at first measurement post-dose from a phase 2 study in 70 adult patients with asthma and blood eosinophil count >200 cells/μL (mean baseline blood eosinophils: 348 cells/μL).1,2

Only NUCALA evaluated and demonstrated lasting eosinophil reduction for 4.5 years3

The mean baseline blood eosinophil level was 240 cells/μL and on-treatment levels were ~40 to 50 cells/μL

Blood eosinophil reduction data based on geometric mean.

Results are descriptive; the clinical significance of these pharmacodynamic data is unknown; mechanism of action of mepolizumab in asthma has not been definitively established.

REFERENCES:

  1. Data on file, GSK.
  2. Pouliquen IJ, Kornmann O, Barton SV, et al. Characterization of the relationship between dose and blood eosinophil response following subcutaneousadministration of mepolizumab. Int J Clin Pharmacol Ther. 2015;53(12):1015-1027.
  3. Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742-1751.
  4. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicenter, double-blind, placebo-controlled trial. Lancet. 2012;380:651-659.